Probiotics and obesity: a limited signal for an antioxidant enzyme in men

Changing a blood marker does not mean improving health. In a 12-week randomized trial in Saudi adults with overweight or obesity, a probiotic blend produced a modest signal for an antioxidant enzyme, mainly in men. No changes in circulating endotoxins or liver enzymes were observed. These results, available here only as a PubMed abstract, do not demonstrate a benefit against obesity.

Illustration of probiotic bacteria and a blood sample used to measure antioxidant enzymes.
SupplementsEditorial illustration, not study data.

A specific blend tested against a placebo

The researchers recruited 93 adults aged 19 to 40 in Riyadh. The trial was randomized, double-blind and placebo-controlled: 44 participants were assigned to the probiotic group and 49 to the placebo group.

The product studied, HEXBIO, contained six bacterial species belonging to the genera Bifidobacterium and Lactobacillus. The placebo contained the same excipients, without live bacteria. The intervention lasted 12 weeks. The abstract also mentions a dietary intervention without specifying what it involved, which limits understanding of the exact trial conditions.

The most relevant finding remains modest

In the probiotic group, concentrations of two antioxidant enzymes, superoxide dismutase and glutathione peroxidase GPX1, increased between the start and end of the study. But a change within one group is not enough to establish a supplement's effect: the comparison with placebo is what matters.

The abstract reports a between-group difference only for GPX1, favoring probiotics. When the results were broken down by sex, favorable changes were seen in men but not in women. The authors describe the effect as modest and call for confirmation.

An antioxidant enzyme is not a clinical outcome

These enzymes contribute to the body's antioxidant defenses. Measuring them can provide information about a biological response, but does not by itself demonstrate a reduction in obesity-related complications. The abstract reports no demonstrated benefit for weight or disease occurrence.

Circulating endotoxins and liver enzymes did not change. The trial therefore does not support a general claim that this blend reduces endotoxins. Nor does it allow the observed signal to be generalized to all probiotics, whose compositions can differ.

What the abstract leaves to be checked

The limited sample size and analysis by sex make confirmation in an adequately powered trial necessary. The size of the between-group difference and its uncertainty are not detailed in the excerpt provided.

The full text was not consulted. Adverse effects, funding and conflicts of interest are not documented in this dossier. The publication can be identified by DOI 10.1097/md.0000000000051573.

Limitations to keep in mind

The analysis is based solely on the PubMed abstract of a trial involving 93 adults followed for 12 weeks. The dietary intervention is insufficiently described, the signal by sex remains to be confirmed, and no clinical benefit has been established. Tolerability, funding and conflicts of interest could not be verified.

What we can take away

This trial suggests a modest biological effect on GPX1 in men, not demonstrated effectiveness of probiotics against obesity. It is not enough to justify buying this supplement to prevent obesity-related complications.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.